EUVIMEDEUVIMED entdecken
Open Access

Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations

Anubhuti Chaturvedi, Reena Tomar, Shramana Mandal, Deepti Goswami, Nita Khurana

Indian Journal of Medical Research · 01.07.2026 · 164 · 98-102

DOI: 10.25259/ijmr_3261_2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Medical Research, online erschienen am 01.07.2026. Verfasst von Anubhuti Chaturvedi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India. Hauptthemen laut MEDLINE: B7-H1 Antigen, Ovarian Neoplasms, Biomarkers, Tumor, Cystadenocarcinoma, Serous. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives The prevalence and significance of programmed death-1 ligand (PD-L1) expression in serous ovarian carcinoma are not well established. This study aimed to evaluate PD-L1 expression using immunohistochemistry (IHC) in whole tissue sections of serous ovarian carcinoma and to correlate its expression with relevant clinicopathological characteristics.

Methods

A retrospective study of 30 cases was conducted at a tertiary care centre in New Delhi, India, over one yr. All cases were reviewed using HandE staining, and IHC for PD-L1 was performed manually on poly-L-lysine–coated slides using the PD-L1 (E1L3N®) XP® Rabbit monoclonal antibody. Additional clinicomorphological data were recorded and analysed.

Results

Based on the combined positive score (CPS) with a 1% cutoff, PD-L1 expression was observed in 33% of cases. PD-L1 expression demonstrated a positive correlation with higher FIGO stage and the presence of tumour-infiltrating lymphocytes (TILs) ( P =0.029). Interpretation and conclusion PD-L1 may serve as a potential prognostic marker in serous ovarian carcinoma. Its expression could help identify patients who may benefit from targeted PD-L1–based therapies and contributes to a better understanding of the biological behaviour of ovarian carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenOvarian NeoplasmsBiomarkers, TumorCystadenocarcinoma, SerousFemaleHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMiddle AgedAdultRetrospective StudiesGene Expression Regulation, NeoplasticAgedPrognosisIndia

Stichwörter der Autor:innen

ImmunohistochemistryOvarian neoplasmsProgrammed death ligand 1 proteinSerous carcinoma

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India.
  • Department of Obstetrics & Gynaecology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India.

Zitieren

APA

Chaturvedi, A., Tomar, R., Mandal, S., Goswami, D., & Khurana, N. (2026). Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations. Indian Journal of Medical Research, 164, 98-102. https://doi.org/10.25259/ijmr_3261_2025

Vancouver

Chaturvedi A, Tomar R, Mandal S, Goswami D, Khurana N. Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations. Indian Journal of Medical Research. 2026;164:98-102. doi:10.25259/ijmr_3261_2025

BibTeX
@article{Chaturvedi2026,
  author = {Chaturvedi, Anubhuti and Tomar, Reena and Mandal, Shramana and Goswami, Deepti and Khurana, Nita},
  title = {Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations},
  journal = {Indian Journal of Medical Research},
  year = {2026},
  volume = {164},
  pages = {98--102},
  doi = {10.25259/ijmr_3261_2025}
}
Kostenlos starten →